Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases

Prion

Volumn 9, Issue 2, 2015, Pages 75-79

  Forloni, Gianluigi ^a   Tettamanti, Mauro ^a   Lucca, Ugo ^a   Albanese, Yasmin ^a   Quaglio, Elena ^a   Chiesa, Roberto ^a   Erbetta, Alessandra ^b   Villani, Flavio ^b   Redaelli, Veronica ^b   Tagliavini, Fabrizio ^b   Artuso, Vladimiro ^c   Roiter, Ignazio ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c CA FONCELLO HOSPITAL   (Italy)

Author keywords

Doxycycline; Neurodegeneration; Preventive treatment in FFI; Prion s diseases; Trial

Indexed keywords

DOXYCYCLINE; PRION PROTEIN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; FAMILIAL INCIDENCE; FATAL FAMILIAL INSOMNIA; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INCIDENCE; INHERITANCE; KNOWLEDGE MANAGEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYSOMNOGRAPHY; RISK ASSESSMENT; GENETICS; INSOMNIA, FATAL FAMILIAL; MIDDLE AGED;

ADULT; CLINICAL TRIALS AS TOPIC; DOXYCYCLINE; HUMANS; INSOMNIA, FATAL FAMILIAL; MIDDLE AGED;

EID: 84944450004     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.1080/19336896.2015.1027857     Document Type: Article

References (16)

1. Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers & Dement. 2013; 9: 123-131; http://dx. doi. org/10. 1016/j. jalz. 2012. 12. 004.
2. Peters KR, Lynn Beattie B, Feldman HH, Illes J. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog Neurobiol. 2013; 110: 114-23; PMID: 23348495; http://dx. doi. org/10. 1016/j. pneurobio. 2012. 12. 001.
3. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet. 2004; 363: 51-61; PMID: 14723996; http://dx. doi. org/10. 1016/S0140-6736(03)15171-9.
4. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012; 11: 618-28; PMID: 22710755; http://dx. doi. org/10. 1016/S1474-4422(12)70063-7.
5. Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992; 326: 444-9.; PMID: 1346338; http://dx. doi. org/10. 1056/NEJM199202133260704.
6. Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, Avoni P, Ferrillo F, Anchisi D, Moresco RM, et al. Pre-symptomatic diagnosis infatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006, 129: 668-75; PMID: 16399807; http://dx. doi. org/10. 1093/brain/awl003.
7. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, PoliG, CaramelliM, Grazia Bruzzone M, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A. 2002; 99: 10849-54; PMID: 12149459; http://dx. doi. org/10. 1073/pnas. 162195499.
8. Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets. 2009; 9: 23-30; PMID: 19200012; http://dx. doi. org/10. 2174/1871526510909010023.
9. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 2008; 3(3): 14-15; PMID: 18365024; http://dx. doi. org/10. 1371/j.
10. Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M. A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem 2013; 56: 5987-6006.; PMID: 23611039; http://dx. doi. org/10. 1021/jm400161p.
11. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro. J. Mol. Biol (2000); 300: 1309-1322.; PMID: 10903871; http://dx. doi. org/10. 1006/jmbi. 2000. 3840.
12. Tagliavini F. Prion therapy: Tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers & Dement 2008; 4 (suppl): T149-T150; http://dx. doi. org/10. 1016/j. jalz. 2008. 05. 373.
13. Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes JR, Imperiale D, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13: 150-8; PMID: 24411709; http://dx. doi. org/10. 1016/S1474-4422(13)70307-7.
14. Assar H, Topakian R, Weis S, Rahimi J, Trenkler J, Höftberger R, Aboulenein-Djamshidian F, Ströbel T, Budka H, Yull H, et al. A case of variably proteasesensitive prionopathy treated with doxycyclin. J Neurol Neurosurg Psychiatry. 2015 Jan 9 [Epub ahead of print]; pii: jnnp-2014-309871; PMID: 25575846; http://dx. doi. org/10. 1136/jnnp-2014-309871.
15. Pocchiari M, Ladogana A. Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2015 Jan 28 [Epub ahead of print]; pii: jnnp-2014-310127; PMID: 25632154; http://dx. doi. org/10. 1136/jnnp-2014-310127.
16. Krasnianski A, Sanchez Juan P, Ponto C, Bartl M, Heinemann U, Varges D, Schulz-Schaeffer WJ, Kretzschmar HA, Zerr I. A proposal of new diagnostic pathway for fatal familial insomnia. J Neurol Neurosurg Psychiatry. 2014; 85: 654-9; PMID: 24249784; http://dx. doi. org/10. 1136/jnnp-2013-305978.